The binding of peptides to MHC class I molecules induces MHC/ peptide complexes that have specific conformational features. Little is known about the molecular and structural bases required for an optimal MHC/peptide association able to induce a dominant T cell response. We sought to characterize the interaction between purified HLA-A3 molecules and four well known CD8 epitopes from HIV-1 proteins. To define the characteristics of HLA-peptide complex formation and to identify potential structural changes, we used biochemical assays that detect well formed complexes. We tested the amplitude, stability, and kinetic parameters of the interaction between HLA-A3, peptides, and anti-HLA mAbs. Our results show that the four epitopes Nef73-82, Pol325-333, Env37-46, and Gag20 -28 bind strongly to HLA-A3 molecules and form very stable complexes that are detected with differential patterns of mAb reactivity. The most striking result is the nonrecognition of the HLA-A3/Gag20 -28 complex by the A11.1M mAb specific to HLA-A3/-A11 alleles. To explain this observation, from the data published on HLA-A11 crystallographic structure, we propose molecular models of the HLA-A3 molecule complexed with Nef73-82, Pol325-333, and Gag20 -28 epitopes. In the HLA-A3/Gag20 -28 complex, we suggest that Arg at position P1 of the peptide may push the ␣2 helix residue Trp-167 of HLA-A3 and affect mAb recognition. Such observations may have great implications for T cell antigen receptor recognition and the immunogenicity of HLA/ peptide complexes. C rystallographic structure analysis of a series of class I MHC/peptide complexes revealed that peptides carrying specific MHC anchor residues bind in a large-solvent-exposed groove of the heavy chain. This binding groove consists of two long helices, ␣1 and ␣2, mounted on a floor of eight antiparallel ␤-strands. Polymorphic residues in the groove determine distinct binding pockets from A to F. Bound peptides adopt extended conformations that stretch from the N-to the C-terminal end of the groove, and their anchor residues, generally at positions P2 and P9/10, interact with pockets B and F, respectively (1-4). In most MHC complexes, peptides are partly buried in the binding site, and only a few side chains of the peptide pointing away from the groove toward the solvent are accessible for CD8 T cell recognition (1, 5).
C
rystallographic structure analysis of a series of class I MHC/peptide complexes revealed that peptides carrying specific MHC anchor residues bind in a large-solvent-exposed groove of the heavy chain. This binding groove consists of two long helices, ␣1 and ␣2, mounted on a floor of eight antiparallel ␤-strands. Polymorphic residues in the groove determine distinct binding pockets from A to F. Bound peptides adopt extended conformations that stretch from the N-to the C-terminal end of the groove, and their anchor residues, generally at positions P2 and P9/10, interact with pockets B and F, respectively (1) (2) (3) (4) . In most MHC complexes, peptides are partly buried in the binding site, and only a few side chains of the peptide pointing away from the groove toward the solvent are accessible for CD8 T cell recognition (1, 5) .
The impact of peptide binding on heavy-chain MHC conformation can be detected serologically by the observation of differential anti-MHC mAbs reactivities. This effect has been mainly documented with murine anti-H2-K b , -K d , and -L d mAbs by testing the expression on mutant cells of class I MHC molecules loaded with synthetic peptides or by performing selective immunoprecipitation of complexes containing different sets of peptide. In those studies, specific residues of the bound peptide essential for mAb recognition were identified, and the impact of exposed, but also buried, peptide residues on ␣1 and ␣2 MHC conformation was demonstrated (6) (7) (8) (9) (10) (11) (12) . The same effect of peptides on mAb recognition of HLA class I molecules also has been observed by studying HLA-B27, -A11, or -B35/-B51 molecules loaded with various peptides and their analogues' ligands. Peptide residues P5, P6, P8, and P9 were identified as influencing the mAb recognition of HLA-B27 and -A11 molecules (5, 13, 14) , whereas the P1 residue was described as being critical for the binding of 4D12 mAb to HLA-B35/-B51 (15) . A more recent study with human mAbs revealed the impact of different peptides on the HLA-A2/peptide complexes and its mAb recognition (16) .
We undertook the present work to analyze peptide-induced alterations in the structure of HLA-A3/peptide complexes by performing multiparametric approaches. HLA-A3 molecules are able to present a large panel of viral CD8 T cell epitopes and to induce very dominant CD8 T cell responses (17) (18) (19) . We used anti-HLA mAbs that can only recognize well folded HLA-A3/ peptide/␤2 microglobulin (␤2m) complexes, and our studies suggest peptide-induced HLA-A3 conformational changes that affect mAb recognition. Molecular modeling indicated the importance of P1 peptide residue and the HLA ␣2 helix.
Results
Purity of HLA Preparations. HLA preparations were analyzed by SDS/PAGE, and the proteins were detected by silver staining and immunoblotting (Fig. 1A) . The pattern of proteins, obtained before and after purification, showed numerous bands in the cell lysate, and only one major band of Ϸ40 kDa and a minor band of Ϸ90 kDa after purification. The first major band corresponds to the molecular mass of the HLA heavy chain (44 kDa), and the second band probably corresponds to a dimeric form of this heavy chain. These results were confirmed by immunoblotting: HCA2 mAb, which recognizes HLA-A3 heavy chains, detected two bands corresponding to monomers (44 kDa) and dimers (90 kDa) of HLA-A3 heavy chains. In the presence of 2-mercaptoethanol, dimeric forms disappeared and monomeric forms augmented ( Fig. 1 A) . Our system of affinity columns coupled to anti-HLA Igs efficiently purified HLA-A3 molecules.
HLA-Peptide Interaction.
To analyze the folding of HLA-A3 molecules in the presence of various epitopes, we tested the recognition of the formed complexes with anti-HLA mAbs of different specificities. We investigated the direct binding of exogenous peptides to purified HLA-A3 molecules and the stability of the complexes formed (Fig. 1B) . We tested four well known epitopes presented to CD8 T cells by HLA-A3 (Gag20-28, Nef73-82, Env37-46, and Pol325-333) ( Table 1) . As negative control, we used an irrelevant peptide from influenza virus, which can be presented by HLA-B27 (NP383-391).
To test HLA-A3/peptide binding, synthetic peptides at concentrations ranging from 10 Ϫ4 to 10 Ϫ10 M were incubated with purified HLA-A3 heavy chains in the presence of exogenous ␤2m. HLA/peptide complexes were trapped by anti-HLA Igs coated on a microplate assay, and the association was then detected with the ␤2m-specific Igs coupled to alkaline phosphatase by fluorescence (Fig. 1B) . By using this method, it is possible to detect only the correctly formed HLA/peptide/␤2m complexes. Representative results obtained with PA2.6 and A11.1M Igs are shown in Table 2 and Fig. 2A . No HLA-A3 complex was detected in the presence of the irrelevant peptide NP383-391. By contrast, the HLA-A3 complexes formed with Gag20 -28, Nef73-82, Env37-49, or Pol325-333 were recognized by the PA2.6 Igs. In addition, A11.1M Igs recognized HLA-A3 complexes formed with Nef73-82, Env37-46, or Pol325-333 but did not recognize the HLA-A3 complexes formed with Gag20-28. These results suggest that the HLA-A3/Gag20-28 complex differs in structure from the other three HLA-A3/peptide complexes and that the serological epitope recognized by A11.1M Igs is masked.
To detect the stability of HLA-A3/peptide complexes, we incubated them at 37°C for times ranging from 0 to 48 h, then trapped them by using PA2.6 or A11.1M Igs. (Figs. 1C and 2B ). The results show that the HLA-A3/peptide complexes detected with A11.1M or PA2.6 Igs were very stable, with a half-life of Ͼ6 h. For the HLA-A3/Gag20-28 complex, no association or stability curve could be observed with A11.1M Igs, but with PA2.6 Binding of various epitopes to purified HLA molecules. HLA molecules were denatured, and heavy chains plus ␤2m were separated from the endogenous peptides then immediately incubated with several concentrations of exogenous peptides for 2 h at room temperature and overnight at 4°C. HLA/peptide complexes were retained on ELISA plates coated with anti-HLA Igs. Correctly folded complexes were detected by using anti-␤2m Ig coupled to alkaline phosphatase (AP) and a fluorescent substrate. (C) Stability of HLA/peptide complexes. Denaturation and binding of HLA molecules with exogenous peptides are described in B. The reassembled HLA/peptide complexes were further incubated at 37°C for times ranging from 0 to 48 h. At each point, the remaining complexes were detected as described before. Anchor residues of the peptide to the HLA molecule are indicated in bold. Igs, the complex was particularly stable with a half-life longer than 24 h.
Surface Plasmon Resonance (SPR).
To confirm the binding results, we used SPR to analyze the kinetic parameters of the interaction between our various Igs and the HLA-A3/peptide complexes. Reconstituted complexes were injected into the BIAcore system, and their association with PA2.6 or A11.1M Igs, linked to anti-mouse Fc rabbit Igs immobilized on the chip, was measured. The kinetic parameters of the Igs-reconstituted complex interaction are summarized in Table 3 . The K D affinities were Ϸ100-200 nM for A11.1M and PA2.6 Igs. With irrelevant peptide or relevant peptide, the affinity of the Igs for HLA-A3 was of the same order, because the presence in our preparation of remaining HLA-A3 complexed with endogenous peptides. Because of the sensitivity of the system, those complexes were recognized by the Igs with an affinity and kinetic parameters similar to those of reconstituted complexes. However, we observed a clear difference in the R max values, which indicates the quantity of complexes bound to the Igs. With A11.1M Ig R max values were of the same order when HLA-A3 was in presence of Gag 20-28 or the irrelevant peptide. These results confirm that A11.1M mAb does not recognize the HLA-A3/Gag20-28 complex. PA2.6 mAb recognized all of the HLA-A3/peptide complexes with R max of the same order of values, except for the negative control. We can notice that PA2.6 mAb recognizes HLA-A3/Gag20-28 complex with a higher R max than the other complexes.
Molecular Model of HLA/Peptide Complexes. To confirm the hypothesis that the HLA-A3/Gag20-28 complex has a different structure that could hide the serological epitope, we analyzed HLA-A3/Nef73-82, Pol325-333, and Gag20-28 complexes by using molecular model structures. Sequence comparison within the region of the binding groove revealed that HLA-A0301 and HLA-A1101 molecules differ only from each other at seven sites. Based on the x-ray crystal structures of HLA-A11 with Nef73-82 and Pol325-333 (20) , three molecular models of the Nef73-82, Pol325-333, or Gag20-28 peptides bound to HLA-A3 were built (Fig. 3A) . For the HLA-A3/Gag20-28 complex, energy minimization was achieved after allowing the side chains to move during the molecular modeling. Superposition of ␣1 and ␣2 helices in the three molecular models shows that the Nef73-82 and Pol325-333 peptides adopt a similar conformation within the groove with nearly identical positioning of their N and C termini.
The exposed residues are Gln-1, Leu-4, Arg-5, and Tyr-9 for Nef73-82; Gln-4, Ser-5, Met-7, and Thr-8 for Pol325-333; and Arg-1, Pro-4, Gly-5, Gly-6, Lys-7, and Lys-8 for Gag20-28 ( Fig.  3B ). In the HLA-A3/Gag20-28 complex, the Arg-1 residue of the peptide induced a clear conformational change of the residue Trp-167 in the ␣2 helix, which became solvent-exposed. This change also influenced the orientation of more distant residues, such as Asp-106 and Arg-169. Another difference in the three molecular model is the solvent accessibility of the peptides: 1,636 Å 2 , 1,495 Å 2 , and 1,625 Å 2 , respectively, for Gag20-28, Pol325-333, and Nef73-82. Because the Nef73-82 peptide contains 10 aa, the accessible surface/amino acid is similar for Nef73-82 and Pol325-333 but is significantly increased for Gag20-28. Therefore, the results of modeling show that the Gag20-28 peptide induced conformational changes in the HLA-A3 binding groove.
HLA-A3 Binding to Peptides
Carrying an Arg at Position P1. To verify the influence of the Arg at P1 of peptide Gag20-28 on the folding of HLA-A3 molecules, two additional epitopes, Nef188-196 and EBNA3A603-611 (Table 1) , also with Arg at P1, were tested for HLA-A3 binding as reported in Fig. 1 . The reconstituted complexes were detected by using A11.1M and PA2.6 Igs and similar patterns of reactivity with HLA-A3/Gag20-28, HLA-A3/Nef188-196, and HLA-A3/EBNA3A603-611 were obtained. The serological epitope recognized by A11.1M mAb seemed to be masked in these three cases (Fig. 4) .
Discussion
Various reports have shown that stability and conformation of MHC/peptide complexes are dependent on the nature of the 
Concentrations of reconstituted heavy chain/␤2m/peptide complexes tested were 250 and 500 nM for A11.1M mAb and 500 nM for PA2.6 mAb. RU, resonance units. bound peptides (6-9, 21, 22) . The HLA-A3 molecule appears highly reactive and can induce strong T cell responses directed to various viral epitopes (17, 18, 23, 24) , but little is known about the molecular and structural determinants underlying this phenomenon. Here, we report some features of the interaction of HLA-A3 with dominant CD8 epitopes, stability of the complexes formed, and their recognition by different anti-HLA mAbs. In our biochemical approach, we showed that purified HLA-A3 molecules interacted strongly with the epitopes tested, and the formed HLA-A3/peptide complexes were stable over 24 h. In addition, differential panels of mAbs reactivity were observed as illustrated by PA2.6, a monomorphic anti-HLA mAb that reacted strongly with all of the HLA-A3/peptide complexes tested, and A11.1M, of more restricted specificity, which did not react with the HLA-A3/Gag20-28 complex. Peptide Gag20-28 possesses an original sequence, including five positive charges that may dramatically influence interactions within the HLA-A3 binding groove. We then tested other epitopes with several positive charges and found that two other HLA-A3 complexes formed with Nef188-196 and EBNA3A603-611 gave a pattern of mAb reactivity similar to that of HLA-A3/Gag20-28. The most striking similarity in the sequence of the three peptides is an Arg at position P1. SPR data showed that PA2.6 mAb bound to the four HLA-A3/peptide complexes tested with similar kinetic constants and Rmax. This may be due to strong stability of all formed complexes and a similar expression of the relevant serological epitope. Nevertheless, our k on and k off rates, as well as K D affinity (60 nM), were of the same order as values obtained with a Fab Ab binding to an HLA-A2/tumor-derived peptide complex (25) . In contrast, by using A11.1M mAb, interaction with HLA-A3 complexes formed with Nef73-82, Pol325-33, and Env37-46 gave very similar kinetic constants and R max , but no interaction with HLA-A3/Gag20-28 complex was detected. Our present results also showed that PA2.6 mAb bound to HLA-A3/peptide complexes with higher R max values than A11.1M mAb. The latter allele-specific mAb probably recognizes a subpopulation of all of the HLA-A3/peptide complexes recognized by PA2.6 mAb, as already reported in other MHC systems (12, 26) . This suggestion is strengthened by the low quantity of HLA-A3 material eluted from the A11.1M mAb column as compared with the HLA material eluted from anti-HLA monomorphic mAbs (data not shown).
Several hypotheses have been proposed to explain the differential mAb recognition of HLA-peptide complexes. First, the serological epitope Ab-binding site may be shaped by solventexposed residues of the peptide, and its recognition may be inhibited (5, 13). Notably, positively charged side chains of P5 and P6 residues of the peptide positioned in the HLA-A11 binding groove may be responsible for the failure of AUF5.13 mAb recognition (5) . Moreover, other studies have shown that the bulkier the side chain of peptide, the greater the inhibition of mAb binding (13, 27) . Concerning HLA-A3, we do not favor this hypothesis, because peptide Gag20-28 at positions P5 and P6 contains two exposed Gly, lacking side chains, and a similar effect was obtained with another HLA-A3 complex formed with Nef84-92 peptide, containing a Ser and a His at P5 and P6, respectively (data not shown). Second, residue P1 of the peptide with part of the A-pocket can form a serological epitope, as illustrated by mAb 4D12 reacting with HLA-B35 (15) . Here, the HLA-A3 complexes formed with Nef188 -196 and EBNA3A603-611, which gave a pattern of mAb reactivity similar to that of HLA-A3/Gag20-28, carry an Arg at P1, but we also observed that several peptides carrying an Ala at P1 can have the same effect (data not shown). This hypothesis also is not very likely. Third, HLA conformational changes induced by peptides may alter serological epitopes and inhibit mAb recognition (6) (7) (8) (9) (10) (11) (12) (13) 28) . Previous crystallographic analysis of HLA-A2, -B8, and -A11 molecules have shown subtle structural differences when various peptides are introduced in the binding groove (20, 22, 29) . To further investigate the hypothesis of structural change, we referred to HLA-A11 complexed with Nef73-82 or Pol325-333 epitopes (20) . In HLA-A11/peptide complexes, different hydrogen-bond networks are possible between the N-terminal end of the binding groove and the peptide, depending on the size of P1 residue side chain. It was shown that Nef73-82 and Pol325-333 peptides bind with a high affinity to the closely related HLA-A3 and -A11 molecules (30) . We also observed that both peptides bind strongly to HLA-A3 and -A11 molecules, and the complexes were similarly recognized by A11.1M and PA2.6 mAbs (data not shown for HLA-A11 molecules). Fitting the Gag20-28 peptide in the HLA-A3 binding groove necessitated changes in pocket A to encompass the bulky Arg at P1 of peptide. The main change occurred on the orientation of Trp-169 in the immediate vicinity of P1 and might involve more distant residues, such as Asp-106 and Arg-169. With all precautions necessary to interpret modeling results, the main conclusion is that the conformational change in HLA-A3 required for Gag20-28 binding corroborates the alteration in complex recognition by conformation-sensitive mAbs. Madden et al. (22) reported that the largest peptide-induced structural differences in HLA-A2 conformation were observed in the ␣2 helix of the heavy chain. In particular, residue Trp-167, which forms part of the solvent-accessible surface of five HLA-A2/ peptide complexes described, could directly affect mAb recognition. In addition, the crystal structure of HLA-B8/EBNA3 peptide complex showed that peptide could induce conformational changes in HLA heavy-chain backbone and side chains that were transmitted along the peptide-binding groove in a domino effect (29) . Chiefly, the partly exposed side chain of Phe at P1 of the peptide pushed the charged side chain ␣1 helix residue Arg-62 out of the A-pocket and the ␣2 helix residue Trp-167 side chain upwards away from the A-pocket. Consequently, the reorientation of HLA-B8 residues Arg-62 and Trp-167 could have an indirect effect on Ab recognition. Because the peptide bound in the binding groove in an extended conformation with conserved hydrogen bonds at its N and C termini, and especially exhibits a lack of flexibility at the peptide N terminus, it is not really surprising that, depending on its size/characteristics, the P1 residue could have a major impact on HLA conformation. An alteration in the mAb binding site in H-2 molecules previously suggested that the peptide residue at P1 impacts on MHC heavy chain structure and our results agree with this suggestion because peptides Gag20-28, Nef188-196, and EBNA3A603-611 carrying an Arg at P1 inhibited A11.1M mAb recognition of HLA-A3/peptide complexes. But various reports also suggest that peptide residues at several positions may alter mAb binding (see the Introduction), demonstrating the complexity of the phenomenon.
In most class I MHC/peptide complexes, the peptide of 9-mers is buried in the MHC binding site, so that only a few side chains of this peptide are accessible for T cell antigen receptor (TCR) recognition. Previous studies have shown that subtle changes in the peptide may alter TCR recognition and hence the functional quality of cytotoxic T lymphocyte responses (5, 31) . In the case of the immunodominant T cell response to HLA-A2/influenza matrix 58-66, the crystallographic analysis revealed that the public V␤17 TCR recognizes a relatively featureless peptide that might be related to the selection of a public repertoire (32) . Indeed, Turner et al. (33) suggested that few exposed peptide side chains will tend to select a limited repertoire of TCRs, whereas several exposed peptide side chains enlarged the T cell recognition repertoire. In line with this, the HLA-A3/Gag20-28 complex, which induces dominant T cell responses in HLA-A3 HIV infected subjects (23, 34) , contains a peptide with several exposed side chain residues. Further studies are needed to establish the degree of enlargement of the TCR repertoire targeting this epitope. MHC/peptide complex/TCR binding suggested frame-shifting within the MHC groove inducing conformational and/or flexibility changes of the binding partners and causing differential T cell stimulation (35) (36) (37) (38) . Upon complex formation with antigens, Abs also undergo conformational changes, as observed in binding to haptens or peptides (39, 40) . In conclusion, our results suggest that conformational readjustments occur at the HLA/peptide complex level independently of the TCR interaction. The impact of consequent conformational remodeling on the specificity and nature of the T cell repertoire remains to be documented.
Materials and Methods
Materials. Anti-HLA mAbs directed against various HLA molecules were used: PA2.6 and W6/32, which recognize HLA -A, -B, and -C (41, 42); A11.1M directed against HLA-A3, -A11, and -A24 (43); and HCA2, which is highly selective for HLA-A and -G heavy chains (44) . The Igs were purified by using protein A Sepharose columns (Amersham Pharmacia, Piscataway, NJ).
All of the peptides were synthesized by NeoMPS (Strasbourg, France). Five HIV-1 epitopes (Gag20-28, RLRPGGKKK; Nef73-82, QVPLRPMTYK; Env37-46, TVYYGVPVMK; Pol325-333, AIFQSSMTK; and Nef188-196, RLAFHHVAR) and one EBV epitope (EBNA3A603-611, RLRAEAGVK) were presented by HLA-A3. One epitope from the influenza virus (NP383-391, SRYWAIRTR) was presented by HLA-B27. The peptides were diluted to 1 mg/ml in water, aliquoted, and stored at Ϫ20°C.
Purification of HLA Molecules. HLA molecules were purified from the cell line transformed by EBV (V4-33 typed HLA-A*0301: B*0801/B*1402: Cw*0701/Cw*0802) by using affinity columns coupled to various Igs. Cells were lysed and supernatants were run through different columns as described previously (45) . Briefly, the columns consisted of CNBr-Sepharose 4B, CNBrSepharose 4B coupled to normal murine Igs, and CNBrSepharose 4B coupled to anti-HLA Igs. HLA molecules were eluted from columns with diethylamine and N-octyl-␤-Dglucopyranoside (Sigma) and then were immediately neutralized. After a dialysis, samples were aliquoted and frozen at Ϫ80°C. Protein concentrations were determined by using the BCA reagent (Pierce, Rockford, IL).
SDS/PAGE.
We analyzed 100 ng of HLA preparations with and without 2-mercaptoethanol by SDS/PAGE. The proteins were detected by silver staining (Silver Stain Plus; Bio-Rad, Hercules, CA) and by immunoblotting. After gel electrophoresis, the proteins were transferred to polyvinylidene difluoride membrane (Immobilon-P; Millipore, Saint-Quentin-en-Yvelines, France). After saturation, the membrane was incubated for 24 h at 4°C with HCA2 mAb (1:200). Then the membrane was incubated for 1-2 h at room temperature with an anti-mouse IgG from sheep linked to peroxidase (Amersham Pharmacia) (1:5,000). The proteins were detected by chemiluminescence (ECL; Amersham Pharmacia).
HLA-Peptide Interactions. The wells of microtiter plates (Nunc Maxisorp) were coated with various anti-HLA mAbs at 10 g/ml in 100 l PBS and incubated at 37°C for 2 h. The plates were washed three times with PBS/Tween 20 and saturated overnight with PBS/Tween 20 containing 1% BSA. HLA molecules (20-50 g) were denatured in 500 l PBS/Tween 20 plus 100 l of PBS/Tween 20 containing 1% BSA plus 200 l of 6 M urea and adjusted to pH 11.7 with 10 l of 1 M NaOH. The mixture was incubated for 1 h at 4°C. HLA heavy chains and ␤ 2 m were separated from endogenous peptides on a Sephadex G25 column (PD10; Amersham Pharmacia) saturated with 1 ml of PBS/ Tween 20 containing 5% BSA and equilibrated with PBS/Tween 20 containing 2 mM EDTA. The first 2.5 ml were discarded, and the next 2.5 ml were immediately mixed with 2 g/ml exogenous ␤ 2 m (Sigma), 6 mM CHAPS (Sigma), and peptide. A volume corresponding to 0.5 g of HLA molecules (corresponding to the quantity of HLA per two wells of the microtiter plate) was incubated with different concentrations of exogenous peptides (10 Ϫ4 to 10 Ϫ10 M) for 2 h at room temperature and then for 24 h at 4°C. After being washed three times with PBS/Tween 20, 100 l of reassembled HLA/peptide complexes were added to the wells of microtiter plates coated with anti-HLA Igs and incubated for 2 h at room temperature. After being washed three times with PBS/Tween 20, correctly folded HLA complexes were revealed with anti-␤2m Ig (M28) coupled to alkaline phosphatase, with 4-methyl-umbelliferyl phosphate as a substrate (M-8883; Sigma). The fluorescence generated was measured at 360/460 nm in a Microfluor reader (Victor 1420; Wallac, Turku, Finland).
HLA/Peptide Complex Stability. HLA denaturation and renaturation with 10 Ϫ5 M exogenous peptides were described before. After overnight incubation, unbound peptides were removed by centrifugation on a Nanosep-10K (Pall Fitron, Northborough, MA). Samples were diluted in PBS/Tween 20 and aliquoted into Eppendorf microtubes for further incubations at 37°C for 1, 2, 4, 6, 24, and 48 h. One aliquot (time 0) was tested immediately to establish the maximum number of complexes formed. Final detection was performed as described above.
SPR.
A BIAcore 3000; the CM5 sensor chip; the P20 surfactant; an amine coupling kit containing N-hydroxysuccinimide and N-ethyl-NЈ-dimethylaminopropyl carbodiimide, and 2-(2-pyridinyldithioethaneamine); and the anti-mouse Fc-␥ polyclonal Abs were from BIAcore (Uppsala, Sweden). The binding of HLA molecules to mAbs was performed at 25°C in Hepesbuffered saline as the running buffer (10 mM Hepes/150 mM NaCl/3.4 mM EDTA/0.02% surfactant P20, pH 7.4). The analyte, the HLA/peptide complexes, and the mAbs were diluted in Hepes-buffered saline. The sensor chip surface was regenerated after each experiment by injection of 30 l of 50 mM HCl. The control Ab was an unrelated IgG2a mAb 34 (IgG2a). Immobilization of the rabbit anti-mouse Fc␥ Abs was performed by the standard procedure provided by BIAcore. Then, the anti-HLA Igs were immobilized to covalently linked rabbit anti-mouse Fc-␥ on the four channels of the chip. Of a solution of 50 nM Igs (PA2.6 and 34) and 100 nM of A11.1M, 30 l were injected at a flow of 2 l/min, followed by a flow of 30 l/min for HLA-A3/peptide complexes at 250 and 500 nM for 5 min,
